azacitidine and Granulocytic Leukemia

azacitidine has been researched along with Granulocytic Leukemia in 115 studies

Research

Studies (115)

Timeframe	Studies, this research(%)	All Research%
pre-1990	17 (14.78)	18.7374
1990's	15 (13.04)	18.2507
2000's	38 (33.04)	29.6817
2010's	42 (36.52)	24.3611
2020's	3 (2.61)	2.80

Authors

Authors	Studies
Amdouni, H; Auberger, P; Benhida, R; Bougrin, K; Driowya, M; Dubois, A; Dufies, M; Furstoss, N; Lacas-Gervais, S; Martin, AR; Métier, C; Orange, F; Robert, G; Zerhouni, M	1
Aumann, K; Brown, MP; Clarson, J; Duyster, J; El Khawanky, N; Hein, L; Hughes, A; Hughes, TP; Lopez, AF; Manz, MG; Matschulla, T; Miething, C; Myburgh, R; Shoumariyeh, K; Taromi, S; Vinnakota, JM; White, DL; Yong, ASM; Yu, W; Zeiser, R	1
Gafter-Gvili, A; Gurion, R; Raanani, P; Sherban, A; Wolach, O	1
Amat, P; Calabuig, M; García, F; Hernández-Boluda, JC; Martín, I; Navarro, B; Remigia, MJ; Solano, C; Tormo, M; Villamón, E	1
Dufva, IH; Gillberg, L; Grønbæk, K; Hajkova, P; Hansen, JW; Jones, PA; Liu, M; Lykkesfeldt, J; Madaj, Z; Mogensen, JB; Nasif, A; Ohtani, H; Rapin, N; Ørskov, AD	1
Bachmaier, G; Berg, JL; Berghold, A; Hatzl, S; Herzog, SA; Mayer, MC; Perfler, B; Reinisch, A; Sill, H; Wölfler, A; Zebisch, A	1
Helleday, T; Henter, JI; Herold, N; Kutzner, J; Myrberg, IH; Olsen, TK; Paulin, CBJ; Rudd, SG; Sanjiv, K; Schaller, T	1
Becker, PS; Buckley, SA; Chen, TL; Estey, EH; Halpern, AB; Hendrie, PC; Huebner, EM; Orlowski, KF; Othus, M; Percival, MM; Pogosova-Agadjanyan, EL; Scott, BL; Stirewalt, DL; Walter, RB	1
Abdelkarim, M; Becker, H; Bullinger, L; Claus, R; Döhner, K; Duyster, J; Gaidzik, VI; Hackanson, B; Kovarbasic, M; Lübbert, M; Pahl, HL; Schmidts, A; Wäsch, R; Wehrle, J; Yalcin, A	1
Andreeff, M; Benton, CB; Boddu, P; Borthakur, G; Cortes, J; Daver, N; DiNardo, CD; Garcia-Manero, G; Jabbour, EJ; Kadia, T; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Patel, K; Ravandi, F; Takahashi, K	1
Iijima, K; Ito, E; Mori, T; Nagano, C; Nishimura, N; Takafuji, S; Terui, K; Toki, T; Uemura, S	1
Booth, S; Cheng, P; Craddock, C; De Santo, C; Fultang, L; Kearns, P; Keeshan, K; Mussai, F; Perry, T; Sarrou, E; Stavrou, V; Wheat, R	1
Albano, F; Anelli, L; Brunetti, C; Carluccio, P; Casieri, P; Coccaro, N; Cumbo, C; Impera, L; Minervini, A; Minervini, CF; Orsini, P; Parciante, E; Ricco, A; Specchia, G; Tota, G; Zagaria, A	1
Alhan, C; Beeker, A; de Groot, M; de Weerdt, O; Hoogendoorn, M; Huls, G; Koedam, J; Kooy, Mv; Laterveer, L; van de Loosdrecht, AA; van der Helm, LH; Veeger, NJ; Vellenga, E	1
Côté, S; Momparler, LF; Momparler, RL	1
Boddy, N; Burrows, F; Pallis, M; Russell, N; Seedhouse, C; Whittall, A	1
Higashihara, M; Horie, R; Nakashima, M; Togano, T; Umezawa, K; Watanabe, M; Watanabe, T	1
Kobayashi, H; Muroi, K; Nagai, T; Ohmine, K; Ozawa, K; Sripayap, P; Tsukahara, T; Uesawa, M	1
Curik, N; Dluhosova, M; Jonasova, A; Stopka, T; Vargova, J; Zikmund, T	1
Alhonen, L; Jantunen, E; Mäntymaa, P; Mustjoki, S; Pirnes-Karhu, S; Uimari, A	1
Bogenberger, JM; Delman, D; Fauble, V; Hansen, N; Mesa, RA; Tibes, R; Valdez, R	1
Cornelison, AM; Cortes, JE; Daver, N; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Ravandi, F; Teng, A	1
Godley, LA; Jasielec, J; Saloura, V	1
Dass, R; De Porre, P; He, J; Thomas, X; Xiu, L	1
Cao, L; Du, XJ; Fang, F; Feng, X; Hu, SY; Li, YH; Li, YP; Li, ZH; Lu, J; Ni, J; Pan, J; Su, GH; Sun, LC; Tao, YF; Wang, J; Wang, NN; Xiao, PF; Xu, LX; Xu, YY; Zhao, H; Zhao, WL	1
Al-Kali, A; Bhagavatula, K; Bogenberger, JM; Delman, DH; Foran, JM; Hansen, N; Mesa, RA; Mohan, J; Oliver, GR; Rakhshan, F; Tibes, R; Wood, T	1
Aburatani, H; Hattori, Y; Ichikawa, D; Kawakami, Y; Matsushita, M; Okamoto, S; Otsuka, Y; Ozawa, K; Suzuki, T; Tanaka, C; Tsutsumida, N; Uchiumi, A	1
Baczyńska, D; Butrym, A; Kuliczkowski, K; Mazur, G; Poręba, R; Rybka, J	1
Andel, J; Autzinger, EM; Burgstaller, S; Geissler, D; Geissler, K; Girschikofsky, M; Greil, R; Halter, B; Hojas, S; Lang, A; Machherndl-Spandl, S; Pfeilstöcker, M; Pichler, A; Pleyer, L; Rogulj, IM; Schlick, K; Sill, H; Sperr, WR; Stauder, R; Thaler, J; Voskova, D; Zebisch, A	1
Cho, SY; Kim, YI; Kim, YJ; Kwon, HS; Lee, HJ; Park, SW; Yang, HS	1
Bokelmann, I; Lyko, F; Mahlknecht, U; Stresemann, C	1
Datta, J; Ghoshal, K; Jacob, ST; Kutay, H; Lucas, DM; Majumder, S; Motiwala, T; Roy, S	1
Chang, H; Chen, G; Feng, Y; Huang, H; Lin, F; Sun, A; Wang, Y; Wu, D	1
Baldwin, AS; Figueroa, ME; Laurenzana, A; Melnick, A; Miller, WH; Paoletti, F; Petruccelli, LA; Pettersson, F	1
Basile, FG	1
Stone, RM	1
Farzaneh, F; Gaymes, TJ; Lea, NC; MacPherson, LJ; Mufti, GJ; Shall, S; Twine, NA	1
Ikezoe, T; Koeffler, HP; Komatsu, N; Nishioka, C; Yang, J; Yokoyama, A	1
Andersson, BS; Champlin, RE; Corn, P; Li, Y; Murray, D; Valdez, BC	1
Harigae, H; Yokoyama, H	1
Aukerman, SL; Brady, H; Heise, C; Hollenbach, PW; Krushel, L; MacBeth, KJ; Nguyen, AN; Ning, Y; Richard, N; Williams, M	1
Issa, JP	1
Leary, C; Lowery-Nordberg, M; Stephens, J; Turturro, F; Veillon, D	1
Agathanggelou, A; Cavenagh, J; Craddock, C; Goodyear, O; McSkeane, T; Moss, P; Novitzky-Basso, I; Ryan, G; Siddique, S; Stankovic, T; Vyas, P	1
Lee, HW; Liu, W; Liu, Y; Rodgers, GP; Wang, R	1
Kondoh, T; Mori, N; Motoji, T; Ohwashi, M; Okada, M; Shimura, H; Shiseki, M; Tomita, K; Wang, YH; Yoshinaga, K	1
Brueckner, B; Hagemann, S; Heil, O; Lyko, F	1
Bose, JR; Brenet, F; Curcio, TJ; Feldman, EJ; Gergis, US; Ippoliti, CM; Mayer, SA; Moh, M; Morawa, E; Ritchie, EK; Roboz, GJ; Scandura, JM; Villegas, L	1
Al-Ali, HK; Cross, M; Hoppe, G; Jaekel, N; Junghanss, C; Krahl, R; Maschmeyer, G; Niederwieser, D	1
Borthakur, G; Brandt, M; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Liu-Dumlao, T; Pierce, S; Quintás-Cardama, A; Ravandi, F	1
Agresta, S; Amrein, PC; Attar, EC; Ballen, KK; Borger, DR; Burke, M; Chen, YB; Edmonds, KM; Emadi, A; Fathi, AT; Foster, J; Hill, C; Iafrate, AJ; Lopez, HU; Matulis, CR; Neuberg, DS; Sadrzadeh, H; Schenkein, DP; Stone, RM; Straley, KS; Yen, KE	1
Ebrahem, Q; Mahfouz, RZ; Ng, KP; Saunthararajah, Y	1
Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B	1
Al-Ali, NH; Alrawi, E; Duong, VH; Epling-Burnette, PK; Field, T; Komrokji, RS; Lancet, JE; List, AF; Perkins, J; Zhang, L	1
Giles, FJ	1
Chen, H; Shi, YJ; Wang, JZ; Wu, SL; Xu, GB; Zhu, Q	1
Bernstein, M; Momparler, LF; Momparler, RL; Shaker, S	1
Leone, G; Lübbert, M; Teofili, L; Voso, MT	1
Buffler, PA; Gunn, L; Leung, K; Ma, X; Smith, MT; Wiemels, JL; Wiencke, JK; Zhang, L; Zheng, S	1
Aventín, A; Brunet, S; Carnicer, MJ; Estivill, C; Lasa, A; Nomdedéu, JF; Sierra, J	1
Dörken, B; Lübbert, M; Sattler, N; Schmelz, K; Tamm, I; Wagner, M	1
Emi, N; Iwai, M; Kinoshita, T; Kiyoi, H; Naoe, T; Ohno, R; Ozeki, K	1
Chernukhin, I; D'Arcy, V; Delgado, MD; Docquier, F; Klenova, E; León, J; Torrano, V	1
Chen, S; Hao, CL; Tang, KJ; Wang, JX; Wang, M; Xing, HY	1
Lübbert, M; Minden, M	1
Hackanson, B; Lübbert, M; Robbel, C; Wijermans, P	1
Camacho, LH; Chanel, S; Guernah, I; Maslak, P; Nimer, S; Pandolfi, PP; Soignet, S; Warrell, R	1
Aggerholm, A; Hassan, M; Hellström-Lindberg, E; Hokland, P; Khan, R	1
Albitar, M; Bennett, JM; de Castro, C; DiPersio, J; Helmer, R; Issa, JP; Kantarjian, H; Klimek, V; Leavitt, R; Nimer, SD; Ravandi, F; Raza, A; Rosenfeld, CS; Saba, H; Shen, L; Slack, J	1
Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE	1
Fenk, R; Graef, T; Haas, R; Kobbe, G; Kuendgen, A; Zohren, F	1
Baylin, S; Carducci, M; Carraway, H; Dauses, T; Dover, G; Galm, O; Gore, SD; Grever, M; Herman, JG; Jiemjit, A; Karp, JE; Manning, J; Mays, A; Miller, CB; Murgo, A; Rudek, MA; Smith, BD; Sugar, E; Weng, LJ; Zhao, M; Zwiebel, J	1
Gattermann, N; Gräf, T; Haas, R; Hildebrandt, B; Hünerlitürkoglu, A; Kobbe, G; Kuendgen, A; Zohren, F	1
Faroun, Y; Gryn, JF; Kaplan, RB; Kennedy, M; Latsko, J; Lech, JA; Lister, J; Rossetti, JM; Shadduck, RK; Sudan, N	1
Abdelkarim, M; Berg, T; Fliegauf, M; Guo, Y; Lübbert, M	1
Blum, W; Byrd, J; Chan, KK; Klisovic, R; Liu, S; Liu, Z; Marcucci, G; Paschka, P; Perrotti, D; Xie, Z	1
Kalberer, CP; Langenkamp, U; Rohner, A; Siegler, U; Wodnar-Filipowicz, A	1
Bruserud, Ø; Ryningen, A; Stapnes, C	1
Dalal, J; Gonzalez, C; Kearns, GL; Peters, C; Tsao, CF	1
Bai, S; Ghoshal, K	1
Chahinian, AP; Greenfield, DS; Holland, JF; Ohnuma, T	1
Case, DC	1
Anderson, NL; Gemmell, MA	1
Breton-Gorius, J; Freund, M; Guichard, J; Katz, A; Mouthon, MA; Titeux, M; Vainchenker, W	1
Jehn, U	1
Doré, BT; Labiberté, J; Momparler, LF; Momparler, RL	1
Aldinucci, D; Da Ponte, A; Gattei, V; Petti, MC; Pinto, A; Zagonel, V	1
Archimbaud, E; Muus, P; Willemze, R	1
Pinto, A; Zagonel, V	1
Honders, MW; Kester, MG; Landegent, JE; Stegmann, AP; Willemze, R	1
Huijgens, PC; Krulder, JW; Neve, P; Wijermans, PW	1
Chomienne, C; Doré, BT; Momparler, RL	1
Fenaux, P; Quesnel, B	1
Camitta, B; Carroll, AJ; Chang, M; Gresik, MV; Raimondi, SC; Ravindranath, Y; Steuber, CP; Weinstein, H	1
Horton, Y; Roddie, PH; Turner, ML	1
Depil, S; Dussart, P; Prin, L; Roche, C	1
Chabner, BA; Coleman, CN; Drake, JC; Stoller, RG	1
Keller, JW; Miller, DS; Vogler, WR	1
Wiernik, PH	1
Preisler, HD; Renick, J; Rustum, YM; Walczak, I	1
Haskell, CM; Koeffler, HP	1
Greenberg, MS	1
Doré, BT; Momparler, RL	1
Abella, E; Alvarado, CS; Chauvenet, A; Dubowy, R; Harris, M; Inoue, S; Krischer, JP; Ravindranath, Y; Ritchey, AK; Wiley, J	1
McCulloch, EA; Yang, GS	1
Chou, TC; Kong, XB; Tong, WP	1
Anderson, K; Coleman, M; Cuttner, J; Schiffer, CA	1
Boyett, J; Kitchens, CS; Kramer, BS; Noyes, WD; Oblon, DJ; Ross, W; Weiner, RS	1
Miura, Y; Sasaki, R	1
Amelotti, F; Barbieri, R; Bernardi, F; Buzzoni, D; Conconi, F; del Senno, L; Marchetti, G; Patracchini, P; Piva, R; Rossi, M	1
Chan, HS; Estrov, Z; Freedman, MH; Weitzman, SS	1
Colly, LP; Lurvink, E; Richel, DJ; Willemze, R	1
Burchenal, JH; Carter, SK	1
Chabner, BA; Drake, JC; Johns, DG	1

Reviews

13 review(s) available for azacitidine and Granulocytic Leukemia

Article	Year
Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis. Leukemia research, 2022, Volume: 113 Topics: Acute Disease; Azacitidine; Decitabine; Disease-Free Survival; Enzyme Inhibitors; Humans; Leukemia, Myeloid; Maintenance Chemotherapy; Randomized Controlled Trials as Topic; Recurrence; Remission Induction; Treatment Outcome	2022
The mechanistic role of DNA methylation in myeloid leukemogenesis. Leukemia, 2014, Volume: 28, Issue:9 Topics: Azacitidine; Clinical Trials as Topic; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Leukemia, Myeloid; Mutation	2014
How I treat patients with myelodysplastic syndromes. Blood, 2009, Jun-18, Volume: 113, Issue:25 Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous	2009
[Management of anemia and bone marrow hypoplasia in the treatment of myeloid leukemia]. Nihon rinsho. Japanese journal of clinical medicine, 2009, Volume: 67, Issue:10 Topics: Anemia; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Bone Marrow Diseases; Clinical Trials as Topic; Decitabine; Drug Design; Erythrocyte Transfusion; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Platelet Transfusion; Practice Guidelines as Topic	2009
Epigenetic changes in the myelodysplastic syndrome. Hematology/oncology clinics of North America, 2010, Volume: 24, Issue:2 Topics: Acetylation; Acute Disease; Azacitidine; Cell Transformation, Neoplastic; Decitabine; DNA Methylation; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myeloid; Methylation; Myelodysplastic Syndromes; Neoplasms; Protein Processing, Post-Translational	2010
New drugs in acute myeloid leukemia. Current oncology reports, 2002, Volume: 4, Issue:5 Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides	2002
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clinical immunology (Orlando, Fla.), 2003, Volume: 109, Issue:1 Topics: Acetylation; Azacitidine; Cytidine; Decitabine; DNA Methylation; Hematologic Neoplasms; Histones; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes	2003
Decitabine in acute myeloid leukemia. Seminars in hematology, 2005, Volume: 42, Issue:3 Suppl 2 Topics: Acute Disease; Azacitidine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Epigenesis, Genetic; Humans; Leukemia, Myeloid	2005
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies. Annals of hematology, 2005, Volume: 84 Suppl 1 Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Epigenesis, Genetic; Humans; Leukemia, Myeloid; Mice; Myelodysplastic Syndromes	2005
DNA methyltransferases as targets for cancer therapy. Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:6 Topics: Antineoplastic Agents; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation; Gene Silencing; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Transcriptional Activation	2007
5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia, 1993, Volume: 7 Suppl 1 Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Decitabine; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes	1993
P15INK4b gene methylation and myelodysplastic syndromes. Leukemia & lymphoma, 1999, Volume: 35, Issue:5-6 Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Carrier Proteins; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 9; Clinical Trials, Phase II as Topic; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinases; Decitabine; Disease Progression; DNA Methylation; Genes, p16; Genes, Tumor Suppressor; Hematopoiesis; Humans; Leukemia, Myeloid; Mice; Myelodysplastic Syndromes; Neoplasm Proteins; Precancerous Conditions; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transforming Growth Factor beta; Tumor Suppressor Proteins	1999
New cancer chemotherapeutic agents. Cancer, 1972, Volume: 30, Issue:6 Topics: Aldehydes; Amides; Amines; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Azaguanine; Bleomycin; Carmustine; Chlorides; Cyclization; Cyclohexanes; Cytarabine; Cytidine; Doxorubicin; Glycosides; Humans; Hydroxyurea; Imidazoles; Leukemia, Lymphoid; Leukemia, Myeloid; Mice; Nitrosourea Compounds; Picolinic Acids; Platinum; Podophyllotoxin; Streptozocin; Thiosemicarbazones; Triazenes	1972

Trials

13 trial(s) available for azacitidine and Granulocytic Leukemia

Article	Year
Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes. Clinical epigenetics, 2019, 10-17, Volume: 11, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Ascorbic Acid; Azacitidine; CpG Islands; Denmark; DNA Methylation; Double-Blind Method; Epigenesis, Genetic; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Pilot Projects	2019
Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study. Leukemia, 2017, Volume: 31, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytarabine; Decitabine; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Recurrence; Treatment Outcome; Young Adult	2017
Targeting the arginine metabolic brake enhances immunotherapy for leukaemia. International journal of cancer, 2019, 10-15, Volume: 145, Issue:8 Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arginase; Arginine; Azacitidine; Humans; Immunotherapy; K562 Cells; Leukemia, Myeloid; Receptors, Chimeric Antigen; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes; Tumor Microenvironment; Vorinostat	2019
Azacytidine causes complex DNA methylation responses in myeloid leukemia. Molecular cancer therapeutics, 2008, Volume: 7, Issue:9 Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cytosine; Decitabine; DNA Methylation; Genome, Human; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis	2008
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood, 2011, Aug-11, Volume: 118, Issue:6 Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Daunorubicin; Decitabine; Diarrhea; DNA Methylation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Humans; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Young Adult	2011
Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leukemia & lymphoma, 2012, Volume: 53, Issue:1 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Constipation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome	2012
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica, 2013, Volume: 98, Issue:4 Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; fms-Like Tyrosine Kinase 3; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Myeloid; Male; Middle Aged; Mutation; Nausea; Nuclear Proteins; Nucleophosmin; Prognosis; Remission Induction; Thalidomide; Treatment Outcome; Vomiting	2013
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models. Leukemia research, 2013, Volume: 37, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Risk Factors; Survival Rate; Time Factors	2013
Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia, 2006, Volume: 20, Issue:2 Topics: Acetylation; Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; DNA Methylation; Drug Administration Schedule; Drug Therapy, Combination; Female; Histones; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Pilot Projects; Transcription, Genetic; Treatment Outcome	2006
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 2006, Apr-15, Volume: 106, Issue:8 Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Disease-Free Survival; DNA Methylation; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Survival Rate	2006
Long-term outcome of postremission chemotherapy for adults with acute myeloid leukemia using different dose-intensities. Leukemia & lymphoma, 1994, Volume: 15, Issue:1-2 Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Germany; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Opportunistic Infections; Patient Acceptance of Health Care; Preleukemia; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vincristine	1994
In vitro and in vivo effects of 5-aza-2'-deoxycytidine (Decitabine) on clonogenic cells from acute myeloid leukemia patients. Leukemia, 1993, Volume: 7 Suppl 1 Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Decitabine; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Remission Induction; Tumor Stem Cell Assay	1993
Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia group B Study. Cancer treatment reports, 1985, Volume: 69, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypotension; Infusions, Parenteral; Kidney Diseases; Leukemia, Myeloid; Male; Middle Aged	1985

Other Studies

89 other study(ies) available for azacitidine and Granulocytic Leukemia

Article	Year
In Vitro and in Vivo Evaluation of Fully Substituted (5-(3-Ethoxy-3-oxopropynyl)-4-(ethoxycarbonyl)-1,2,3-triazolyl-glycosides as Original Nucleoside Analogues to Circumvent Resistance in Myeloid Malignancies. Journal of medicinal chemistry, 2017, 02-23, Volume: 60, Issue:4 Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Glycosides; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mice, Nude; Myelodysplastic Syndromes; Triazoles; Tumor Cells, Cultured	2017
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nature communications, 2021, 11-08, Volume: 12, Issue:1 Topics: Acute Disease; Animals; Azacitidine; Cell Line, Tumor; Cells, Cultured; Cytotoxicity, Immunologic; DNA Methylation; Enzyme Inhibitors; HEK293 Cells; HL-60 Cells; Humans; Immunotherapy, Adoptive; Interleukin-3 Receptor alpha Subunit; Kaplan-Meier Estimate; Leukemia, Myeloid; Mice, Knockout; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Single-Chain Antibodies; Xenograft Model Antitumor Assays	2021
Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples. Anticancer research, 2019, Volume: 39, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Curcumin; Drug Synergism; Female; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes	2019
miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms. Annals of hematology, 2021, Volume: 100, Issue:11 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Decitabine; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid; MicroRNAs; THP-1 Cells	2021
With me or against me: Tumor suppressor and drug resistance activities of SAMHD1. Experimental hematology, 2017, Volume: 52 Topics: Acute Disease; Animals; Antimetabolites, Antineoplastic; Autoimmune Diseases of the Nervous System; Azacitidine; Cell Line, Tumor; Cell Proliferation; Cytarabine; Decitabine; Drug Resistance; Humans; Leukemia, Myeloid; Monomeric GTP-Binding Proteins; Mutation; Nervous System Malformations; SAM Domain and HD Domain-Containing Protein 1; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins	2017
The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. Experimental hematology, 2017, Volume: 55 Topics: Acute Disease; Azacitidine; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Decitabine; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Myeloid; Oligodendrocyte Transcription Factor 2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; U937 Cells	2017
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia. Leukemia & lymphoma, 2018, Volume: 59, Issue:9 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Decitabine; Drug Administration Schedule; Humans; Leukemia, Myeloid; Middle Aged; Mutation; Remission Induction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53	2018
Effective response to azacitidine in a child with a second relapse of myeloid leukemia associated with Down syndrome after bone marrow transplantation. Pediatric blood & cancer, 2018, Volume: 65, Issue:12 Topics: Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Child, Preschool; Down Syndrome; Female; Humans; Leukemia, Myeloid; Neoplasm Recurrence, Local	2018
Droplet digital PCR for the quantification of Alu methylation status in hematological malignancies. Diagnostic pathology, 2018, Dec-22, Volume: 13, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Alu Elements; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Feasibility Studies; Female; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Polymerase Chain Reaction; Predictive Value of Tests; Reproducibility of Results; Retrospective Studies	2018
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leukemia research, 2013, Volume: 37, Issue:8 Topics: Acute Disease; Aged; Aged, 80 and over; Azacitidine; Bone Marrow; Bone Marrow Cells; Cell Count; Compassionate Use Trials; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Remission Induction; Retrospective Studies	2013
Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C). Leukemia research, 2013, Volume: 37, Issue:8 Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Survival; Cytarabine; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Approval; HL-60 Cells; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration	2013
Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC pharmacology & toxicology, 2013, Jun-15, Volume: 14 Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Azacitidine; Cell Line, Tumor; Cell Survival; Clofarabine; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Flavonoids; Heterocyclic Compounds, 4 or More Rings; Humans; Leukemia, Myeloid; Piperidines; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Sirolimus; TOR Serine-Threonine Kinases	2013
Synergistic effect of 5-azacytidine and NF-κB inhibitor DHMEQ on apoptosis induction in myeloid leukemia cells. Oncology research, 2012, Volume: 20, Issue:12 Topics: Apoptosis; Azacitidine; Benzamides; Cell Line, Tumor; Cyclohexanones; Drug Synergism; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; NF-kappa B; Tumor Cells, Cultured	2012
Mechanisms of resistance to azacitidine in human leukemia cell lines. Experimental hematology, 2014, Volume: 42, Issue:4 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Division; Drug Resistance, Neoplasm; G2 Phase; HL-60 Cells; Humans; Leukemia, Myeloid; Point Mutation; Uridine Kinase	2014
Epigenetic control of SPI1 gene by CTCF and ISWI ATPase SMARCA5. PloS one, 2014, Volume: 9, Issue:2 Topics: Acute Disease; Adenosine Triphosphatases; Animals; Azacitidine; CCCTC-Binding Factor; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genomic Imprinting; HeLa Cells; Humans; Immunoblotting; Insulin-Like Growth Factor II; K562 Cells; Leukemia, Erythroblastic, Acute; Leukemia, Myeloid; Microscopy, Confocal; Protein Binding; Proto-Oncogene Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Long Noncoding; Trans-Activators	2014
Spermidine/spermine N(1)-acetyltransferase activity associates with white blood cell count in myeloid leukemias. Experimental hematology, 2014, Volume: 42, Issue:7 Topics: Acetyltransferases; Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Humans; Leukemia, Myeloid; Leukocyte Count; Male; Mice; Mice, Inbred C57BL; Polyamines	2014
Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leukemia & lymphoma, 2015, Volume: 56, Issue:1 Topics: Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Leukemia, Myeloid; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides	2015
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes. Leukemia & lymphoma, 2015, Volume: 56, Issue:2 Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Proportional Hazards Models; Retrospective Studies	2015
Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study. Leukemia & lymphoma, 2015, Volume: 56, Issue:4 Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Decitabine; Disease-Free Survival; Erythrocyte Transfusion; Humans; Leukemia, Myeloid; Multivariate Analysis; Outcome Assessment, Health Care; Platelet Transfusion; Randomized Controlled Trials as Topic; Remission Induction	2015
Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients. International journal of molecular medicine, 2014, Volume: 34, Issue:6 Topics: Acute Disease; Azacitidine; Cell Line, Tumor; Child; Decitabine; DNA Methylation; DNA-Binding Proteins; Down-Regulation; Enzyme Inhibitors; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Neoplasm, Residual; Prognosis; Promoter Regions, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; U937 Cells	2014
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. Journal of hematology & oncology, 2015, Oct-20, Volume: 8 Topics: Acute Disease; Aged; Aged, 80 and over; Anilides; Antimetabolites, Antineoplastic; Azacitidine; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Drug Synergism; Female; Hedgehog Proteins; High-Throughput Nucleotide Sequencing; HL-60 Cells; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Pyridines; RNA Interference; Signal Transduction	2015
Identification of Novel HLA-A24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies. PloS one, 2016, Volume: 11, Issue:1* Topics: Azacitidine; Case-Control Studies; Cell Line, Tumor; Cells, Cultured; Decitabine; Epitopes; HLA-A24 Antigen; Homeodomain Proteins; Humans; Leukemia, Myeloid; Monocytes; Neoplastic Stem Cells; T-Lymphocytes, Cytotoxic	2016
Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients. Oncotarget, 2016, May-24, Volume: 7, Issue:21 Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Gene Expression Regulation, Leukemic; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; MicroRNAs; Middle Aged; Prognosis; Remission Induction; Treatment Outcome; Young Adult	2016
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. Journal of hematology & oncology, 2016, Apr-16, Volume: 9 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Austria; Azacitidine; Female; France; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Registries; United Kingdom; United States; World Health Organization	2016
Inhibin-α gene mutations and mRNA levels in human lymphoid and myeloid leukemia cells. International journal of oncology, 2017, Volume: 50, Issue:4 Topics: Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; Decitabine; DNA Methylation; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibins; Leukemia, Lymphoid; Leukemia, Myeloid; Loss of Heterozygosity; Mutation; Promoter Regions, Genetic; RNA, Messenger	2017
PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells. The Journal of biological chemistry, 2009, Jan-02, Volume: 284, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Azacitidine; Cell Transformation, Neoplastic; CpG Islands; DNA Methylation; DNA Modification Methylases; Enzyme Activation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Interphase; Isoenzymes; K562 Cells; Leukemia, Myeloid; Mice; Nuclear Proteins; Phosphorylation; Receptor-Like Protein Tyrosine Phosphatases, Class 3; STAT5 Transcription Factor	2009
Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. European journal of haematology, 2009, Volume: 82, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Neoplasm Proteins; Oxides; RNA, Messenger; Transcription, Genetic; Xenograft Model Antitumor Assays	2009
Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. Cancer research, 2009, Jan-01, Volume: 69, Issue:1 Topics: Acetylation; Acute Disease; Azacitidine; Cell Differentiation; Chromatin; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Inhibitors; Histones; Humans; Leukemia, Myeloid; Monocytes; NF-kappa B; NF-kappa B p50 Subunit; Promoter Regions, Genetic; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Transcription Factor RelA; Tumor Necrosis Factor-alpha; U937 Cells	2009
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide. Leukemia & lymphoma, 2009, Volume: 50, Issue:4 Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide	2009
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes. Haematologica, 2009, Volume: 94, Issue:5 Topics: Apoptosis; Azacitidine; Benzamides; Butyrates; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Decitabine; DNA Modification Methylases; DNA Repair; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Fluorobenzenes; Histone Acetyltransferases; HL-60 Cells; Humans; Hydroxamic Acids; Immunohistochemistry; K562 Cells; Leukemia, Myeloid; Myelodysplastic Syndromes; Phenanthrenes; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Pyridines; U937 Cells	2009
Blockade of MEK signaling potentiates 5-Aza-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells. International journal of cancer, 2009, Sep-01, Volume: 125, Issue:5 Topics: Acetylation; Aged; Apoptosis; Azacitidine; Benzimidazoles; Blotting, Western; Cell Proliferation; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase Inhibitor p21; Decitabine; DNA Modification Methylases; Drug Synergism; Enzyme Inhibitors; Flow Cytometry; Gene Expression Regulation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myeloid; MAP Kinase Kinase 1; Middle Aged; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Transfection; Tumor Cells, Cultured	2009
5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leukemia research, 2010, Volume: 34, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Blotting, Western; Busulfan; Cell Line, Tumor; Cell Separation; Decitabine; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, cdc; Humans; In Situ Nick-End Labeling; Leukemia, Myeloid; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction	2010
A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PloS one, 2010, Feb-02, Volume: 5, Issue:2 Topics: Acute Disease; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Blotting, Western; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Decitabine; DNA Damage; DNA Methylation; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression; HL-60 Cells; Humans; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Protein Biosynthesis; Repressor Proteins	2010
Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-01, Volume: 28, Issue:22 Topics: Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Chromosome Deletion; Female; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes	2010
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood, 2010, Sep-16, Volume: 116, Issue:11 Topics: Acute Disease; Aged; Aged, 80 and over; Amino Acid Sequence; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cluster Analysis; Female; Flow Cytometry; Gene Expression Profiling; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid; Male; Melanoma-Specific Antigens; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Cytotoxic; U937 Cells; Valproic Acid	2010
Olfactomedin 4 is a novel target gene of retinoic acids and 5-aza-2'-deoxycytidine involved in human myeloid leukemia cell growth, differentiation, and apoptosis. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Cycle Proteins; Cell Differentiation; Cell Proliferation; Decitabine; DNA Methylation; Electrophoretic Mobility Shift Assay; Gene Expression; Gene Expression Regulation, Neoplastic; Granulocyte Colony-Stimulating Factor; HL-60 Cells; Humans; Immunohistochemistry; Leukemia, Myeloid; Myeloid Cells; Phosphoproteins; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin	2010
Aberrant methylation of the RIZ1 gene in myelodysplastic syndrome and acute myeloid leukemia. Leukemia research, 2011, Volume: 35, Issue:4 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Decitabine; DNA Methylation; DNA-Binding Proteins; Female; Gene Expression; Histone-Lysine N-Methyltransferase; HL-60 Cells; Humans; Leukemia, Myeloid; Male; Middle Aged; Molecular Sequence Data; Myelodysplastic Syndromes; Nuclear Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Sequence Analysis, DNA; Transcription Factors; U937 Cells; Young Adult	2011
Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PloS one, 2011, Mar-07, Volume: 6, Issue:3 Topics: Azacitidine; Chromatin; CpG Islands; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Genes, Neoplasm; Genome, Human; HCT116 Cells; HL-60 Cells; Humans; Leukemia, Myeloid; Oligonucleotide Array Sequence Analysis; Protein Binding; Transcription Factors; Tumor Suppressor Proteins	2011
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood, 2012, Dec-06, Volume: 120, Issue:24 Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Epigenesis, Genetic; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid; Male; Multivariate Analysis; Mutation; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome	2012
Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood, 2012, Nov-29, Volume: 120, Issue:23 Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; DNA Mutational Analysis; Female; Glutarates; Granulocyte Precursor Cells; Humans; Idarubicin; Isocitrate Dehydrogenase; Leukemia, Myeloid; Male; Middle Aged; Mutation; Prospective Studies; Time Factors	2012
High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects. Oncotarget, 2012, Volume: 3, Issue:10 Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytidine Deaminase; Decitabine; Humans; Leukemia, Myeloid; Liver; Liver Neoplasms; Mice; Mice, Knockout; Tetrahydrouridine; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2012
[Inhibitory effect on proliferation of KG1a cell line by methyltransferase inhibitors]. Zhongguo shi yan xue ye xue za zhi, 2002, Volume: 10, Issue:4 Topics: Azacitidine; Cell Cycle Proteins; Cell Differentiation; Cell Division; Cell Line; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid; Tumor Suppressor Proteins	2002
Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leukemia research, 2003, Volume: 27, Issue:5 Topics: Acetylation; Acute Disease; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Azacitidine; Cell Division; Decitabine; Depsipeptides; DNA Methylation; DNA Replication; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histones; HL-60 Cells; Humans; Hydroxamic Acids; Leukemia, Myeloid; Neoplasm Proteins; Peptides, Cyclic; Protein Processing, Post-Translational; Tumor Cells, Cultured; Tumor Stem Cell Assay	2003
Hypermethylation of the 5' CpG island of the FHIT gene is associated with hyperdiploid and translocation-negative subtypes of pediatric leukemia. Cancer research, 2004, Mar-15, Volume: 64, Issue:6 Topics: Acid Anhydride Hydrolases; Adolescent; Antimetabolites, Antineoplastic; Azacitidine; B-Lymphocytes; Child; Child, Preschool; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 21; CpG Islands; Decitabine; Diploidy; DNA Methylation; DNA, Neoplasm; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Male; Neoplasm Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; T-Lymphocytes; Translocation, Genetic; Tumor Cells, Cultured	2004
MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias. Leukemia, 2004, Volume: 18, Issue:7 Topics: Acute Disease; Adult; Azacitidine; Bone Marrow; Case-Control Studies; Cell Line, Tumor; Core Binding Factor Alpha 2 Subunit; Decitabine; DNA Methylation; Down-Regulation; Homeodomain Proteins; Humans; Hydroxamic Acids; Leukemia, Myeloid; Myeloid Ecotropic Viral Integration Site 1 Protein; Neoplasm Proteins; Oncogene Proteins, Fusion; Promoter Regions, Genetic; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Transcription Factors	2004
Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms. Leukemia, 2005, Volume: 19, Issue:1 Topics: Acute Disease; Apoptosis; Azacitidine; Base Sequence; Cell Division; Decitabine; DNA Methylation; DNA Primers; Epithelial Cells; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Polymerase Chain Reaction	2005
Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome. Leukemia, 2005, Volume: 19, Issue:8 Topics: Acid Anhydride Hydrolases; Acute Disease; Azacitidine; Bone Marrow; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes; Neoplasm Proteins; Recurrence; RNA, Messenger; Tumor Suppressor Proteins	2005
CTCF regulates growth and erythroid differentiation of human myeloid leukemia cells. The Journal of biological chemistry, 2005, Jul-29, Volume: 280, Issue:30 Topics: Azacitidine; Blotting, Northern; Blotting, Western; CCCTC-Binding Factor; Cell Differentiation; Cell Lineage; Cell Proliferation; Cytidine Triphosphate; DNA-Binding Proteins; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; K562 Cells; Leukemia, Myeloid; Oligonucleotides, Antisense; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic; Transfection; Zinc Fingers	2005
[5-Aza-2'-deoxycytidine enhances differentiation and apoptosis induced by phenylbutyrate in Kasumi-1 cells]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:3 Topics: Acute Disease; Apoptosis; Azacitidine; CD11b Antigen; CD13 Antigens; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Decitabine; Dose-Response Relationship, Drug; Drug Synergism; Humans; Leukemia, Myeloid; Phenylbutyrates	2005
A pharmacodynamic study of 5-azacytidine in the P39 cell line. Experimental hematology, 2006, Volume: 34, Issue:1 Topics: Apoptosis; Azacitidine; Cadherins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Humans; Leukemia, Myeloid; Methylation; Myogenic Regulatory Factors; Time Factors	2006
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol. Pediatric blood & cancer, 2007, Volume: 48, Issue:3 Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine	2007
Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leukemia research, 2007, Volume: 31, Issue:2 Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Recurrence; Remission Induction; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2007
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer research, 2006, Jun-15, Volume: 66, Issue:12 Topics: Acetylation; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Dose-Response Relationship, Drug; Feasibility Studies; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Promoter Regions, Genetic; Treatment Outcome	2006
Induction of complete remission in a patient with acute myeloid leukemia refractory to high-dose chemotherapy through treatment with 5-azacytidine. Leukemia research, 2007, Volume: 31, Issue:3 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatal Outcome; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Middle Aged; Predictive Value of Tests; Prognosis; Remission Induction	2007
Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer, 2006, Oct-15, Volume: 107, Issue:8 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow; Drug Administration Schedule; Female; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Outpatients; Retrospective Studies	2006
Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leukemia research, 2007, Volume: 31, Issue:4 Topics: Azacitidine; Core Binding Factor Alpha 2 Subunit; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Leukemia, Myeloid; Oncogene Proteins, Fusion; RUNX1 Translocation Partner 1 Protein; Transcription, Genetic; Tumor Cells, Cultured	2007
Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic acids research, 2007, Volume: 35, Issue:5 Topics: Acute Disease; Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Chromatography, Liquid; Clinical Trials, Phase I as Topic; Decitabine; Deoxycytidine; Deoxyguanosine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Humans; Leukemia, Myeloid; Tandem Mass Spectrometry	2007
Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leukemia research, 2007, Volume: 31, Issue:10 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bryostatins; Cell Differentiation; Cell Line, Tumor; Cholecalciferol; Cytotoxicity, Immunologic; Decitabine; Flow Cytometry; GPI-Linked Proteins; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Leukemia, Myeloid; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin; Up-Regulation	2007
Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting. Leukemia research, 2007, Volume: 31, Issue:9 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Cycle; Cell Differentiation; Cell Proliferation; Decitabine; DNA, Mitochondrial; Enzyme Inhibitors; Epigenesis, Genetic; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Phenylbutyrates; Thymidine; Tumor Cells, Cultured; Tumor Stem Cell Assay	2007
Azacitidine pharmacokinetics in an adolescent patient with renal compromise. Journal of pediatric hematology/oncology, 2007, Volume: 29, Issue:5 Topics: Acute Disease; Adolescent; Azacitidine; Chimerism; Dose-Response Relationship, Drug; Drug Administration Schedule; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Recurrence; Renal Insufficiency; Treatment Outcome	2007
Sequential combination of pyrazofurin and 5-azacytidine in patients with acute myelocytic leukemia and carcinoma. Oncology, 1981, Volume: 38, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Amides; Azacitidine; Carcinoma; Carcinoma, Small Cell; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Ribonucleosides; Ribose	1981
5-azacytidine in refractory acute leukemia. Oncology, 1982, Volume: 39, Issue:4 Topics: Acute Disease; Adult; Aged; Agranulocytosis; Azacitidine; Chemical and Drug Induced Liver Injury; Humans; Infusions, Parenteral; Leukemia; Leukemia, Myeloid; Middle Aged; Muscular Diseases	1982
Protein-pattern changes and morphological effects due to methionine starvation or treatment with 5-azacytidine of the phorbol-ester-sensitive cell lines HL-60, CCL-119, and U-937. Clinical chemistry, 1984, Volume: 30, Issue:12 Pt 1 Topics: Azacitidine; Cell Line; Cell Nucleus; Cytoskeleton; Electrophoresis, Polyacrylamide Gel; Humans; Isoelectric Focusing; Leukemia, Myeloid; Lymphoma; Methionine; Protein Biosynthesis; Proteins; T-Lymphocytes; Tetradecanoylphorbol Acetate	1984
Growth and differentiation of the human megakaryoblastic cell line (ELF-153): a model for early stages of megakaryocytopoiesis. Blood, 1994, Aug-15, Volume: 84, Issue:4 Topics: Acute Disease; Antigens, CD; Azacitidine; Cell Differentiation; Cell Division; Cell Line; Cytochalasin B; Cytokines; Fibroblast Growth Factor 2; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Leukemia, Myeloid; Megakaryocytes; Microscopy, Immunoelectron; Models, Biological; Receptors, Cytokine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured	1994
5-Aza-2'-Deoxycytidine and DNA Methyltransferase Inhibitors in the Treatment of Myeloid Leukemias and Myelodysplastic Syndromes: Biological Aspects and Clinical Results. Proceedings of a workshop. Rome, Italy, November 3, 1991. Leukemia, 1993, Volume: 7 Suppl 1 Topics: Animals; Antineoplastic Agents; Azacitidine; Decitabine; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes	1993
Interaction of 5-aza-2'-deoxycytidine with amsacrine or 1,25-dihydroxyvitamin D3 on HL-60 myeloid leukemic cells and inhibitors of cytidine deaminase. Leukemia, 1993, Volume: 7 Suppl 1 Topics: Amsacrine; Antineoplastic Agents; Azacitidine; Calcitriol; Decitabine; Drug Interactions; Drug Screening Assays, Antitumor; Humans; Leukemia, Myeloid; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay	1993
Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia, 1993, Volume: 7 Suppl 1 Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Agents; Azacitidine; Decitabine; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction	1993
Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine. Leukemia, 1993, Volume: 7, Issue:7 Topics: Acute Disease; Animals; Antineoplastic Agents; Azacitidine; Binding, Competitive; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; In Vitro Techniques; Kinetics; Leukemia, Myeloid; Rats; Rats, Inbred BN; Tumor Cells, Cultured	1993
Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia, 1997, Volume: 11, Issue:1 Topics: Acute Disease; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Azacitidine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia	1997
Effect of 5-aza-2'-deoxycytidine and vitamin D3 analogs on growth and differentiation of human myeloid leukemic cells. Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:4 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Differentiation; Cholecalciferol; Decitabine; Dose-Response Relationship, Drug; Drug Interactions; HL-60 Cells; Humans; In Vitro Techniques; Leukemia, Myeloid	1998
Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study Leukemia, 2000, Volume: 14, Issue:7 Topics: Adolescent; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human; Cohort Studies; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Life Tables; Male; Multicenter Studies as Topic; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Remission Induction; Risk Assessment; Risk Factors; Survival Analysis; Thioguanine; Translocation, Genetic; Treatment Failure; Treatment Outcome; United States	2000
Primary acute myeloid leukaemia blasts resistant to cytokine-induced differentiation to dendritic-like leukaemia cells can be forced to differentiate by the addition of bryostatin-1. Leukemia, 2002, Volume: 16, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Azacitidine; Bryostatins; CD40 Ligand; Cell Differentiation; Child; Cytokines; Dendritic Cells; Drug Resistance; Drug Synergism; Female; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-D Antigens; Humans; Hydroxamic Acids; Immunophenotyping; In Situ Hybridization, Fluorescence; Interleukin-12; Interleukin-4; Karyotyping; Lactones; Leukemia, Myeloid; Lymphocyte Culture Test, Mixed; Macrolides; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha	2002
Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients. Leukemia, 2002, Volume: 16, Issue:2 Topics: Acute Disease; Adult; Aged; Azacitidine; Computer Systems; Endogenous Retroviruses; Female; Gamma Rays; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Viral; Genes, gag; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Neoplastic Stem Cells; Phytohemagglutinins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic	2002
Deoxycytidine kinase: properties of the enzyme from human leukemic granulocytes. Blood, 1975, Volume: 46, Issue:5 Topics: Azacitidine; Blood Proteins; Cell Separation; Cell-Free System; Cytarabine; Cytidine Deaminase; Deoxycytidine; Granulocytes; Humans; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukocytes; Molecular Weight; Phosphates; Phosphotransferases; Tissue Extracts; Uridine Kinase	1975
5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. Blood, 1976, Volume: 48, Issue:3 Topics: Agranulocytosis; Azacitidine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Nausea; Neoplasm Metastasis; Vomiting	1976
The therapy of acute leukemia in the adult: a progress report. Hamatologie und Bluttransfusion, 1976, Volume: 19 Topics: Acute Disease; Adult; Antineoplastic Agents; Azacitidine; Blood Transfusion; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocytes; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Patient Isolation; Platelet Transfusion; Pneumonia; Prednisone; Pyrimethamine; Remission, Spontaneous; Thioguanine; Vincristine; Zinostatin	1976
Separation of leukemic cells into proliferative and quiescent subpopulations by centrifugal elutriation. Cancer research, 1977, Volume: 37, Issue:11 Topics: Azacitidine; Bone Marrow; Cell Division; Cell Separation; Centrifugation; Cytarabine; Humans; In Vitro Techniques; Leukemia, Lymphoid; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Thymidine	1977
Rhabdomyolysis as a complication of 5-azacytidine. Cancer treatment reports, 1978, Volume: 62, Issue:4 Topics: Adult; Azacitidine; Female; Humans; Leukemia, Myeloid; Muscular Diseases	1978
Reversible renal dysfunction due to 5-azacytidine. Cancer treatment reports, 1979, Volume: 63, Issue:5 Topics: Aged; Azacitidine; Female; Humans; Kidney Diseases; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged	1979
Effects of 5-aza-2'-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells. Anti-cancer drugs, 1992, Volume: 3, Issue:3 Topics: Antineoplastic Agents; Azacitidine; Blotting, Northern; Cell Differentiation; Decitabine; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interferon-alpha; Leukemia, Myeloid; Oncogenes; RNA, Neoplasm; Tumor Cells, Cultured	1992
Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood, 1992, Nov-01, Volume: 80, Issue:9 Topics: Acute Disease; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Azacitidine; Child; Chromosome Aberrations; Chromosome Disorders; Cytarabine; Daunorubicin; Down Syndrome; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Prednisone; Remission Induction; Thioguanine; Vincristine	1992
A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia. Hematologic pathology, 1992, Volume: 6, Issue:3 Topics: Acute Disease; Antineoplastic Agents; Azacitidine; Blast Crisis; Cell Survival; Cytarabine; Humans; Leukemia, Myeloid; Tumor Cells, Cultured	1992
Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine. Molecular pharmacology, 1991, Volume: 39, Issue:2 Topics: Azacitidine; Base Sequence; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; DNA, Neoplasm; Drug Resistance; Enzyme Induction; Humans; Kinetics; Leukemia, Experimental; Leukemia, Myeloid; Methylation; Molecular Sequence Data; Time Factors; Tritium; Tumor Cells, Cultured	1991
Intensive short-term chemotherapy for patients with acute myelogenous leukemia: long-term follow-up. Cancer treatment reports, 1985, Volume: 69, Issue:12 Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Thioguanine	1985
Effect of 5-azacytidine on the differentiation of human leukemia K-562 cells. International journal of cell cloning, 1986, Volume: 4, Issue:3 Topics: Azacitidine; Benzidines; Cell Differentiation; Cell Line; Cell Survival; DNA; DNA (Cytosine-5-)-Methyltransferases; Dose-Response Relationship, Drug; Histocytochemistry; Humans; Leukemia, Experimental; Leukemia, Myeloid	1986
Methylation and expression of c-myc and c-abl oncogenes in human leukemic K562 cells before and after treatment with 5-azacytidine. Cancer detection and prevention, 1986, Volume: 9, Issue:1-2 Topics: Azacitidine; Cell Differentiation; Cell Line; DNA Restriction Enzymes; DNA, Neoplasm; Humans; Leukemia, Myeloid; Methylation; Nucleic Acid Hybridization; Oncogenes	1986
The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Male; Mercaptopurine; Mitoxantrone; Thioguanine	1987
Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. British journal of cancer, 1988, Volume: 58, Issue:6 Topics: Animals; Antineoplastic Agents; Azacitidine; Bone Marrow; Cell Cycle; Colony-Forming Units Assay; Cytarabine; Decitabine; DNA; Dose-Response Relationship, Drug; Female; Leukemia, Myeloid; Rats; Rats, Inbred BN; Time Factors	1988
Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Biochemical pharmacology, 1973, Nov-01, Volume: 22, Issue:21 Topics: Aminohydrolases; Azacitidine; Blood Proteins; Carbon Radioisotopes; Chromatography, Ion Exchange; Cytarabine; Cytidine; Deamination; Humans; In Vitro Techniques; Kinetics; Leukemia, Myeloid; Leukocytes; Spectrophotometry, Ultraviolet	1973